Introduction
 The p53 protein plays an important role in protecting from cancer. In part, this reflects its ability to inhibit proliferation or eliminate cells that have the potential for malignant progression but more recently, we have found that p53 can also contribute to protecting cells from DNA damage.
We are interested in understanding the signals that induce p53 and the functions of p53 that contribute to its ability to prevent cancer progression.
Ultimately, we hope to be able find ways to reactivate p53 for cancer therapy.
Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Lab Report
 Link to Vousden Scientific Report 2008 135.36 Kb
Key PublicationsBensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-20.
Yang Y, Ludwig RL, Jensen JP, Pierre S, Medaglia MV, Davydov I, Safiran YJ, Oberi P, Kenten J, Phillips AC, Weissman AM, Vousden KH (2005). Small molecule inhibitors of HDM3 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7, 547-59.
Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH (2003). Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577-8.
Nakano K, Vousden KH (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7, 683-94.
Kubbutat MH, Jones SN, Vousden KH ((1997). Regulation of p53 stability by Mdm2. Nature 387, 299-300.
Crook T, Marston NJ, Sara EA, Vousden KH (1994). Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79, 817-27.
Biography
Education and qualifications
1982: PhD, University of London, Supervisor Lorna Casselton
1978: BSc, Genetics and Microbiology (First Class Honours), University of London
Appointments
2002-present: Director, Beatson Institute for Cancer Research, Glasgow
1999-2002: Laboratory Chief, NCI-FCRDC, USA
1998-1999: Interim Director, ABL Basic Research Programme, USA
1995-1998: Laboratory Director, ABL Basic Research Programme, USA
1987-1995: Group Head, Ludwig Institute for Cancer Research, London
1985-1987: Visiting Fellow with Doug Lowy, NCI, USA
1981-1985: Postdoctoral Fellow with Chris Marshall, ICR, London
Honours and awards
The Sir Frederick Gowland Hopkins Memorial Medal Lecture, 2008
The Mike Price Lecture, 2008
Honorary DSc, University of Strathclyde, 2008
Fellow of the Academy of Medical Sciences, 2006
Honorary DSc, University of London, 2006
Fellow of the Royal Society of Edinburgh, 2004
Member of EMBO, 2004
Tom Connors Award Lecture, BACR, 2003
Wellcome Trust Lecture, BSCB, 2003
Fellow of the Royal Society, 2003
NIH Merit Award for Major Contributions to Research, 2001
Tenovus Gold Medal for Contributions to the Field of Gene Expression, 1998
Recent Publications
Carter S, Vousden KH (2008). p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 7, 2519-28.
Horn HF, Vousden KH (2008). Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 27, 5774-84.
Yee KS, Vousden KH (2008). Contribution of membrane localization to the apoptotic activity of PUMA. Apoptosis 13, 87-95.
Carter S, Vousden KH (2008). A role for Numb in p53 stabilization. Genome Biology 9, 221.
Carter S, Bischof O, Dejean, Vousden KH. (2007). C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biology 9, 428-435.
Lukashchuk N, Vousden KH (2007). Ubiquitination and degradation of mutant p53. Mol Cell Biol. 27, 8284-95.
Uldrijan S, Pannekoek WJ, Vousden KH. (2007). An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO Journal 26, 102-112.
Bell HS, Dufes C, O’Prey J, Crighton D, Bergamaschi D, Lu X, Schatzlein AG, Vousden KH and Ryan KM (2007). A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest. 117, 1008-18.
Vikhanskaya F, Toh WH, Dulloo I, Wu Q, Boominatahn L, Ng HH, Vousden KH, Sabapathy K (2007). p73 supports cellular growth through c-Jun-dependent AP-1 transactivation. Nat Cell Biol. 9, 698-706.
Wilson JM, Henderson G, Black F, Sutherland A, Ludwig RL, Vousden KH, Robins DJ. (2007). Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells. Bioorganic & Medicinal Chemistry 15, 77-86.
Yang Y, Kitagaki J, Dai R-M, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, Li C-CH, Kenten JH, Beutler JA, Vousden KH, Weissman AM (2007). Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67, 9472-81.
Bensaad K, Vousden KH (2007). p53: new roles in metabolism. Trends Cell Biol. 17, 286-91.
Horn HF, Vousden KH (2007). Coping with stress: multiple ways to activate p53. Oncogene 26, 1306-16.
Meier P, Vousden KH (2007). Lucifer’s labyrinth – ten years of path finding in cell death. Mol Cell. 28, 746-54.
Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol. 8, 275-83.
Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-20.
Vousden KH. (2006). Outcomes of p53 activation – spoilt for choice. Journal of Cell Science 119, 5015-20.
|
